Suppr超能文献

口服避孕药使用者子宫内膜中纤溶酶原激活物含量降低。

Reduced plasminogen activator content of the endometrium in oral contraceptive users.

作者信息

Casslén B, Astedt B

出版信息

Contraception. 1983 Aug;28(2):181-8. doi: 10.1016/0010-7824(83)90017-3.

Abstract

Human endometrium was found to contain two different plasminogen activators, urokinase and tissue activator. Urokinase was released in higher amounts from endometrial tissue explants obtained in the midcycle phase than from those obtained in the luteal phase. Plasminogen activator activity of the culture medium followed the same pattern. Treatment of postmenopausal patients with ethinylestradiol resulted in liberation of urokinase and tissue activator from endometrial explants in concentrations similar to those found in the normal midcycle phase. In contrast, treatment with oral contraceptives (OCs), containing ethinylestradiol and a progestagen, resulted in lowered release of both activators, even lower than was found during the normal luteal phase. Also the amounts of extractable urokinase from endometrial tissue samples were significantly lower in OC-users than in non-users. Estradiol seems to have a stimulatory effect on the release of plasminogen activators from the endometrium; whereas, gestagens depress the content and release of activators. The low content of plasminogen activators in the endometrium explains the reduced menstrual bleedings found in OC-users.

摘要

研究发现,人子宫内膜含有两种不同的纤溶酶原激活剂,即尿激酶和组织激活剂。与黄体期获取的子宫内膜组织外植体相比,在月经周期中期获取的组织外植体释放出的尿激酶量更多。培养基中的纤溶酶原激活剂活性也呈现相同模式。用乙炔雌二醇治疗绝经后患者,可使子宫内膜外植体释放尿激酶和组织激活剂,其浓度与正常月经周期中期相似。相比之下,用含有乙炔雌二醇和孕激素的口服避孕药(OCs)进行治疗,则会导致两种激活剂的释放量降低,甚至低于正常黄体期的水平。此外,OCs使用者子宫内膜组织样本中可提取的尿激酶量也显著低于非使用者。雌二醇似乎对子宫内膜纤溶酶原激活剂的释放具有刺激作用;而孕激素则会抑制激活剂的含量和释放。子宫内膜中纤溶酶原激活剂含量较低,这解释了OCs使用者月经出血量减少的现象。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验